- New alliance will crack down on adulterated products touting dietary supplement claims
- FDA should consult advisory committees on DXM issue
- FDA approves Merck's Gardasil for prevention of anal cancer
- FDA approves Novartis drug for high blood pressure treatment
- Merck's hepatitis C drug granted priority review by FDA
FRANKLIN LAKES, N.J. — The Food and Drug Administration has approved a second product in BD's new line of injectable drugs, the company said Tuesday.
BD Rx, the pharmaceutical arm of the medical technology manufacturer, whose name stands for Becton, Dickinson and Co., received FDA approval for metoclopramide, part of its BD Simplist line of ready-to-administer pre-filled generic injectables. The product is an antiemetic, a drug used to stop vomiting.
The company previously launched BD Simplist diphenhydramine hydrochloride injection, an antihistamine, last month. The company plans to launch 20 to 30 products in the line over the next few years.
"After a successful launch of BD Simplist pre-filled injectables, we're excited to be coming out with a second drug that is commonly used by clinicians," BD Rx president Mark Sebree said. "This is just the beginning of our new line of pre-filled injectable products."
The company said that every injection carries the potential for medication error, but while traditional vial and syringe injections, clinicians perform up to 20 steps; with the BD Simplist syringes, the sequence is reduced to about 12 steps.